Agency
Ali Hazimeh PLLC
Ali Hazimeh PLLC was paid $5.83M by Medicaid between Apr 2020 and Dec 2024, across 135 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 31% of everything it billed.
33Billing provider infoALI HAZIMEH PLLC
DEARBORN, MI 48126
DEARBORN, MI 48126
33aNPI1437796216assigned 11/29/2019
33bProvider typeHome Health Agency
28Total paid$5.83M
24GClaims167,944
24DCodes billed135
24AFirst – last monthApr 2020 – Dec 2024
Compared with peers
Next to other Home Health Agency providers in Michigan
Rank by total paid#58 of 328
Median peer was paid$697K
This provider vs. median8.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 8,598 | $310K | |
| 2021 | 31,959 | $1.40M | |
| 2022 | 54,235 | $1.73M | |
| 2023 | 36,912 | $1.21M | |
| 2024incomplete | 36,240 | $1.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 31% | 29,066 | 25,121 | $1.79M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 26% | 19,858 | 17,161 | $1.54M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 17% | 14,558 | 14,232 | $997K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 9.8% | 20,074 | 17,267 | $571K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.0% | 1,265 | 1,230 | $118K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.8% | 998 | 938 | $104K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.8% | 3,357 | 3,047 | $103K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.7% | 2,240 | 2,078 | $97K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 11,234 | 7,925 | $71K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.2% | 971 | 828 | $68K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,831 | 2,382 | $52K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 726 | 718 | $42K |
123 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,653 | $27K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,245 | $19K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 255 | $19K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 261 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,201 | $16K |
| S9083 | Global fee urgent care centers | <1% | 316 | $13K |
| 97597 | <1% | 289 | $11K | |
| 81025 | <1% | 1,866 | $9K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,778 | $9K |
| 99205 | Prolong outpt/office vis | <1% | 71 | $8K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 313 | $8K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 848 | $7K |
| 93000 | <1% | 1,065 | $7K | |
| 81002 | <1% | 3,514 | $7K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 161 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 847 | $6K |
| 99001 | <1% | 7,637 | $6K | |
| 81001 | <1% | 3,849 | $5K | |
| 20552 | <1% | 179 | $5K | |
| 99201 | <1% | 132 | $4K | |
| 72100 | <1% | 189 | $4K | |
| 29540 | <1% | 270 | $3K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 66 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,007 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 735 | $3K |
| 86580 | <1% | 583 | $3K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 99 | $3K |
| 99000 | <1% | 3,796 | $3K | |
| 87631 | <1% | 767 | $3K | |
| 73560 | <1% | 186 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,392 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 136 | $2K |
| 99401 | <1% | 120 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 112 | $2K |
| 73120 | <1% | 126 | $2K | |
| 80305 | <1% | 229 | $2K | |
| 99473 | <1% | 230 | $1K | |
| 86328 | <1% | 57 | $1K | |
| 73630 | <1% | 75 | $1K | |
| 73130 | <1% | 75 | $1K | |
| 87428 | <1% | 38 | $1K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,160 | $1K |
| 80306 | <1% | 158 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,307 | $1K |
| 83037 | <1% | 186 | $782.28 | |
| 57410 | <1% | 59 | $744.86 | |
| 90686 | <1% | 93 | $713.32 | |
| 73620 | <1% | 67 | $700.54 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 110 | $676.92 |
| 0001A | <1% | 35 | $605.60 | |
| 29280 | <1% | 66 | $550.31 | |
| 29530 | <1% | 41 | $512.36 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 26 | $482.60 |
| 73600 | <1% | 31 | $471.66 | |
| 82962 | <1% | 249 | $468.64 | |
| 73020 | <1% | 49 | $460.28 | |
| 69210 | <1% | 14 | $439.15 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 125 | $435.60 |
| 96127 | <1% | 173 | $431.25 | |
| 87070 | <1% | 176 | $348.94 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 70 | $345.30 |
| 74019 | <1% | 15 | $266.15 | |
| 99406 | <1% | 68 | $251.42 | |
| 90715 | <1% | 77 | $238.17 | |
| 29130 | <1% | 12 | $229.02 | |
| 90658 | <1% | 12 | $191.78 | |
| 29260 | <1% | 13 | $176.91 | |
| 82948 | <1% | 107 | $151.21 | |
| 99459 | <1% | 14 | $148.57 | |
| 87807 | <1% | 15 | $131.29 | |
| 73030 | <1% | 12 | $125.26 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 186 | $118.18 |
| 36410 | <1% | 1,360 | $105.73 | |
| 15853 | <1% | 12 | $88.35 | |
| 99407 | <1% | 14 | $87.35 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 383 | $78.58 |
| 99173 | <1% | 207 | $75.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14 | $74.48 |
| 90653 | <1% | 16 | $59.53 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 484 | $50.05 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 91 | $48.49 |
| 96160 | <1% | 19 | $30.02 | |
| 86317 | <1% | 13 | $24.82 | |
| 90656 | <1% | 12 | $22.35 | |
| 81000 | <1% | 69 | $13.32 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 16 | $11.00 |
| 94760 | <1% | 946 | $8.40 | |
| 81005 | <1% | 13 | $7.16 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 53 | $2.32 |
| 3077F | <1% | 1,097 | $1.84 | |
| 3080F | <1% | 898 | $1.43 | |
| 3079F | <1% | 249 | $0.39 | |
| 3075F | <1% | 263 | $0.35 | |
| 3351F | <1% | 66 | $0.11 | |
| 3078F | <1% | 81 | $0.05 | |
| 3051F | <1% | 14 | $0.05 | |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | <1% | 272 | $0.02 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 15 | $0.01 |
| 4004F | <1% | 186 | $0.01 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 0% | 64 | $0.00 |
| 3044F | 0% | 85 | $0.00 | |
| 90651 | 0% | 57 | $0.00 | |
| H0033 | Oral medication administration, direct observation | 0% | 32 | $0.00 |
| 90619 | 0% | 29 | $0.00 | |
| A4253 | Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips | 0% | 16 | $0.00 |
| 3074F | 0% | 44 | $0.00 | |
| 90716 | 0% | 27 | $0.00 | |
| 1111F | 0% | 21 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 15 | $0.00 |
| S9470 | Nutritional counseling, dietitian visit | 0% | 220 | $0.00 |
| G8712 | Antibiotic not prescribed or dispensed | 0% | 169 | $0.00 |
| S3005 | Performance measurement, evaluation of patient self assessment, depression | 0% | 43 | $0.00 |
| 90461 | 0% | 108 | $0.00 | |
| 99080 | 0% | 143 | $0.00 | |
| 90707 | 0% | 26 | $0.00 | |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 152 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 66 | $0.00 |
| 90633 | 0% | 19 | $0.00 | |
| 90713 | 0% | 17 | $0.00 | |
| 97602 | 0% | 14 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 18 | $0.00 |
| 90710 | 0% | 12 | $0.00 | |
| 90700 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAZIMEH, ALI (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Hazimeh Primary Care PLLC | Dearborn, MI | $498K |
| Inpatient Care Specialists PLLC | Dearborn, MI | $214K |
| HMC Urgent Care Gross Pointe PLLC | Detroit, MI | $31K |
| HMC Urgent Care Wayne PLLC | Dearborn Heights, MI | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.